Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
LW8 demonstrated strong anti-tumor efficacy in vivo and caused a decrease in HIF-1alpha expression in frozen-tissue immunohistochemical staining
2019 Feb 21
InChi: InChI=1S/C27H29N5O/c28-26-25-24(21-8-4-9-23(14-21)33-17-19-6-2-1-3-7-19)16-32(27(25)30-18-29-26)22-12-20(13-22)15-31-10-5-11-31/h1-4
Carceller V
32(3):799-806
VX-770 Size:2mg solid LW8 demonstrated strong anti-tumor efficacyVX 770, is a drug used to treat cystic fibrosis in people with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, who account for 45% cases of cystic fibrosis, and is included in a combination drug, lumacaftor ivacaftor, which is used to treat people with cystic fibrosis who have the F508del mutation in CFTR. Ivacaftor is a "potentiator" of CFTR, meaning it increases the probability that the defective channel
US$ 199.00
US$ 2899.50
US$ 2000.00
US$ 1874.50
US$ 120.00
US$ 19.99
US$ 1774.50
US$ 1874.50
US$ 14.99